Donepezil Transdermal Composition for Long-Term Impurity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Percutaneous absorption preparations of donepezil suffer from instability due to impurity formation during storage, failing to meet the criteria of the U.S. Pharmacopoeia's Procedure 1 and Procedure 2, especially under long-term conditions, and existing stabilizers do not effectively inhibit impurities across both short-term and long-term periods.
Innovation Solution
A percutaneous absorption preparation comprising donepezil with a stabilizer combination of thiocyanate salt and tea catechin, (+)-catechin, epigallocatechin gallate, ascorbic acid, or isoascorbic acid, or a mixture of monothioglycerol with these compounds, along with a drug-containing layer and a release liner, to maintain stability and reduce impurity formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If percutaneous absorption preparations are formulated with high concentration of donepezil to produce systemic action, then the therapeutic effect is improved, but impurity formation increases during storage due to environmental factors such as heat, light, and moisture
Solution Approach 1:
The patent introduces stabilizers (antioxidants and chelating agents) as intermediary substances that mediate between donepezil and environmental factors. These stabilizers act as protective intermediaries that scavenge free radicals and chelate metal ions, preventing direct interaction between environmental stressors and donepezil, thereby reducing impurity formation while maintaining high drug concentration for therapeutic effect
Solution Approach 2:
The patent changes the chemical environment parameters by adding stabilizers that alter the oxidation-reduction potential and metal ion availability in the formulation. This parameter change creates a more stable chemical environment that prevents donepezil degradation, allowing high concentration formulation to maintain both therapeutic efficacy and storage stability
2Stability of the object's composition
If existing stabilizers are used to inhibit impurity formation, then short-term stability is improved, but long-term stability does not meet U.S. Pharmacopoeia criteria
Solution Approach 1:
The patent merges multiple stabilizing mechanisms by combining antioxidants (such as ascorbic acid, tocopherol) with chelating agents (such as EDTA, citric acid) in a synergistic formulation. This combination approach addresses both short-term oxidative degradation and long-term metal-catalyzed decomposition, enabling the preparation to meet U.S. Pharmacopoeia criteria for both short-term and long-term storage stability
Solution Approach 2:
The patent creates a composite stabilization system that integrates multiple functional components with different stabilization mechanisms. This composite approach combines substances with complementary properties that work together to provide comprehensive protection against various degradation pathways, ensuring stability meets pharmacopeial standards across extended storage periods
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The preparation meets the impurity criteria of Procedure 1 and Procedure 2 of the U.S. Pharmacopoeia under both short-term and long-term storage conditions, ensuring improved stability and compliance with pharmaceutical standards.
Implementation Method 1
various environmental factors such as heat, light, and moisture cause donepezil to produce impurities
Implementation Method 2
Impurities generated from decomposition of a principal component substance
Data Source
AI summary
A percutaneous absorption preparation for the treatment of dementia wherein the drug-containing layer contains donepezil or a pharmaceutically acceptable salt thereof as an active ingredient and a stabilizer that is either (i) a mixture of a thiocyanate salt and a compound selected from the group consisting of tea catechin, (+)-catechin, epigallocatechin gallate, ascorbic acid, and isoascorbic acid, or (ii) a mixture of monothioglycerol and a compound selected from the group consisting of tea catechin, (+)-catechin, epigallocatechin gallate, and ascorbic acid is disclosed. The percutaneous absorption preparation meets the criteria of Procedure 1 and Procedure 2 of the U.S. Pharmacopoeia in short-term stress test (70° C. 48 hours storage), long-term accelerated test 1 (40° C. relative humidity 75% 1 month storage), and long-term accelerated test 2 (40° C. relative humidity 75% 3 months storage), and exhibits improved stability for long-term preservation.